Actively Recruiting
Effect of Semaglutide in Patients With Psoriasis and Obesity
Led by The University of Hong Kong · Updated on 2025-05-13
14
Participants Needed
1
Research Sites
26 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the effects of semaglutide, a medication that may help with weight loss and has potential anti-inflammatory benefits, on adults with both psoriasis and obesity. Psoriasis patients with obesity often face more severe disease and higher risks such as psoriatic arthritis. This open-label, single-arm pilot trial aims to explore whether semaglutide can reduce psoriasis severity alongside weight loss. The study is sponsored by The University of Hong Kong and targets Chinese adults with moderate to severe psoriasis and obesity or overweight conditions. Participants will receive semaglutide injections once weekly, starting at 0.25 mg and continuing up to 2.0 mg over 24 weeks. This treatment is combined with lifestyle changes including a reduced-calorie diet and increased physical activity. Standard psoriasis care will continue throughout the study. The trial includes a 4-week screening period before treatment and a 12-week safety follow-up after the final dose to monitor participant health. During the approximately 36 weeks of participation, patients will undergo evaluations including the Psoriasis Area and Severity Index (PASI) to measure changes in skin condition. Researchers will also monitor treatment adherence, safety, and any side effects. The main goal is to assess the change in psoriasis severity before and after semaglutide treatment. The study allows previous systemic immunosuppressant use and focuses on adults aged 18 to 75 years with specific body mass index criteria and stable psoriasis treatment.
CONDITIONS
Brief Title
Effect of Semaglutide in Patients With Psoriasis and Obesity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinical diagnosis of psoriatic disease for at least 6 months before consent
- Women who are sexually active and not postmenopausal must agree to abstain or use two effective contraception methods
- Age between 18 and 75 years
- Body mass index (BMI) of 30 kg/m2 or greater, or 27 kg/m2 or greater with at least one weight-related comorbid condition such as hypertension, type 2 diabetes mellitus, or dyslipidemia
- Moderate to severe psoriasis with PASI score 5 or higher
- Chinese ethnicity
- On a stable dose of standard psoriasis treatment
- Ability to comply with study requirements
You will not qualify if you...
- Refusal to give consent
- Contraindication to GLP1 receptor agonists
- History of pancreatitis
- History of multiple endocrine neoplasia (MEN) or medullary thyroid carcinoma (MTC)
- Known hypersensitivity to semaglutide or its excipients
- Type 1 diabetes
- Gallbladder disease
- Active malignancy or malignancy within the past 5 years
- Active chronic or acute infection requiring systemic treatment within 4 weeks before baseline
- Pregnancy or breastfeeding
- History of allergic reaction related to the investigational product
- Major psychiatric illness
- Treatment with live or attenuated vaccine within 28 days prior to randomization
- History of alcohol or substance abuse within 6 months prior to screening
- History of suicidal attempts or active suicidal thoughts
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 24 weeks
Participants receive weekly subcutaneous injections of Semaglutide as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in obesity or overweight.
Weekly visits for 24 weeks
Trial Site Locations
Total: 1 location
1
The University of Hong Kong, Department of Medicine
Hong Kong, Hong Kong
Actively Recruiting
Research Team
M
Man Ho Martin Chung
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here